Physician profile
Robert S Mathieu
NPI 1659377315
$2,783.73
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $659 · 2021: $1,141 · 2022: $367.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $602.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $256.65 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $225.30 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $214.08 | 2020-2021 | |
| Pfizer INC. | $204.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $164.74 | 2020-2021 | |
| Novo Nordisk INC | $141.53 | 2019-2022 | |
| Amgen INC. | $140.97 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $91.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $67.83 | 2020-2022 | |
| Amarin Pharma, INC. | $64.14 | 2021 | |
| Abbvie INC. | $61.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.40 | 2019 | |
| Astellas Pharma US INC | $50.96 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50.21 | 2019-2020 | |
| Viiv Healthcare Company | $38.30 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.34 | 2021-2022 | |
| Abbott Laboratories | $34.20 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.33 | 2022 | |
| Eisai INC. | $27.35 | 2021 | |
| Insmed, INC. | $23.65 | 2021 | |
| Esperion Therapeutics, INC. | $20.13 | 2021 | |
| Bardy Diagnostics, INC. | $19.24 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $19.05 | 2020 | |
| Gilead Sciences, INC. | $17.73 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.97 | 2022 | |
| Janssen Biotech, INC. | $12.40 | 2019 | |
| Almatica Pharma LLC | $12.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mathieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.